ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Computational Chemistry

SRI and Exscientia partner on AI-assisted cancer drug discovery

by Craig Bettenhausen
May 8, 2020 | APPEARED IN VOLUME 98, ISSUE 18

 

09818-buscon13-sri.jpg
Credit: SRI International
The flow synthesis module of SRI's system can prepare molecules at the gram scale based on AI-planned routes.

A new partnership aims to design and synthesize oncology drugs using artificial intelligence (AI). Exscientia, one of C&EN’s 10 Start-Ups to Watch in 2017, designs drug candidates using an AI-assisted approach. But the molecules have been synthesized the old-fashioned way. Now Exscientia will deploy SRI’s SynFini system, which uses AI to plan synthetic routes and executes them on a flow-chemistry platform. Combining the technologies has “tremendous potential to further accelerate the oncology drug-discovery process,” says Nathan Collins, SRI’s chief strategy officer.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment